Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
June 7, 2016
Arthur N. Brodsky, Ph.D.
New strategies use alternative ways to promote anti-cancer immunity.
ASCO, bladder cancer, checkpoint-inhibitor, colorectal cancer, kidney cancer, melanoma
ASCO, CAR T cell therapy, checkpoint-inhibitor, leukemia, lung cancer, lymphoma
Anti-PD-1 blockade and two other types of immunotherapy effective in treating multiple tumor types.
AACR, checkpoint-inhibitor, head and neck cancer, skin cancer
AACR, checkpoint-inhibitor, combination therapy
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung cancer.
checkpoint-inhibitor, FDA approval, lung cancer, PD-1
anti-CTLA-4, checkpoint-inhibitor, combination therapy, FDA approval, melanoma
One of the most prestigious prizes in biology, the Lasker is considered a precursor to the Nobel.
awards & honors, checkpoint-inhibitor, James Allison, scientific leadership
checkpoint-inhibitor, clinical trials, melanoma